We welcome inquiries, tips, letters to the editor, and article ideas from the MBS community. Reach us at [email protected] — your submissions help shape what we cover.

Invited surgeon commentaries are forthcoming. If you are interested in contributing a perspective or editorial on a topic relevant to metabolic and bariatric surgery, please contact us at [email protected].

MBS Delivers 5× Greater Lifetime ASCVD Risk Reduction Than GLP-1RA Therapy in Mayo Clinic Head-to-Head Cohort

In this retrospective cohort study of 812 patients (579 MBS, 233 GLP-1RA) treated at Mayo Clinic from 2020 to 2023, metabolic and bariatric surgery produced substantially greater improvement in lifetime atherosclerotic cardiovascular disease (ASCVD) risk than GLP-1 receptor agonist therapy. The adjusted β for lifetime ASCVD was −6.92 (95% CI −9.22 to −4.62): lifetime risk fell 8.6% with MBS versus 1.7% with GLP-1RA (P<0.001). Ten-year ASCVD risk was not significantly different between groups (−0.8% vs. −1.1%, P=.36) — an important nuance indicating the surgical advantage is concentrated in the long-term cardiometabolic horizon driven by superior weight loss (−27.8% vs. −11.1%, P<0.001). LDL-C decreased 15.5 vs. 4.6 mg/dL; HDL-C increased 8.1 vs. 2.1 mg/dL (both P<0.0001). RYGB and BPD-DS demonstrated the greatest lifetime ASCVD reductions among MBS procedure subtypes.

Machine Learning Models Predict Post-Bariatric Weight Loss With AUC 0.846 — But All 12 Studies Carry High Risk of Bias by PROBAST+AI Framework

This systematic review and meta-analysis pooled 12 studies and 13,640 patients to assess the diagnostic performance of machine learning prediction models for weight loss outcomes after metabolic and bariatric surgery; 8 studies contributed to the quantitative synthesis. The pooled area under the curve (AUC) was 0.846 (95% CI 0.755–0.908), suggesting clinically useful discriminative ability in isolation. However, heterogeneity was high (I²=75.4%, p=0.0021), and PROBAST+AI quality assessment rated all 12 studies as having high risk of bias — a unanimous finding that substantially tempers confidence in the pooled estimate. TRIPOD+AI reporting adherence was similarly suboptimal. The most commonly employed algorithms were K-nearest neighbors (KNN), support vector machines (SVM), and Random Forest. External validation and prospective testing were absent in the large majority of studies, leaving the clinical translatability of these models unproven.

BPD-DS Reduces Lifetime ASCVD Risk by 10.5 Points — More Than 3× the Benefit of Sleeve in 2,642-Patient Cohort

This retrospective cohort study enrolled 2,642 patients at a tertiary academic center: 699 undergoing laparoscopic sleeve gastrectomy, 1,813 Roux-en-Y gastric bypass, and 130 biliopancreatic diversion with duodenal switch, all requiring complete baseline and one-year laboratory data. Primary outcomes were 10-year and lifetime ASCVD risk calculated via pooled cohort equations. At one year, mean 10-year cardiovascular risk decreased by 0.33 (LSG), 0.93 (RYGB), and 1.58 (BPD-DS; p=0.006); mean lifetime cardiovascular risk decreased by 3.24, 7.67, and 10.49 points, respectively (p<0.001). The dose-response relationship across procedure types — with more metabolically intensive operations producing greater cardiovascular risk reduction — was consistent and statistically robust. The study’s findings directly complement the Ghusn et al. data in this issue and provide a large-scale procedural context for the observation that RYGB and BPD-DS drive the greatest ASCVD benefit in the head-to-head MBS vs. GLP-1RA comparison.

Long-Term Durability and Metabolic Outcomes of Primary Bariatric Procedures: An Updated Systematic Review — Obesity Reviews

This Obesity Reviews article (doi:10.1111/obr.70142) was selected for Section A but could not be retrieved for summarization due to publisher access restrictions at the time of production. The article is accessible through institutional library access or direct subscription to Obesity Reviews (Wiley). Content summary will be provided in an updated version of this issue as access is obtained. We encourage readers to access the full text directly via the DOI link below.

Boston Scientific Q1 2026 Earnings Beat Resets MedTech Growth Expectations — Shares Jump 8.99%

Boston Scientific reported first-quarter 2026 results that exceeded analyst estimates on both revenue and profitability, sending BSX shares up 8.99% on April 22 to close at $64.87 — the single largest MedTech gainer in the session and among the standout performances of the April earnings season. The beat followed a period of significant intraperiod weakness in which BSX had declined approximately 9% from its April 11 level amid broader tariff-driven MedTech sector volatility; the Q1 report provided a fundamental catalyst that partially reversed that drawdown. Management maintained full-year guidance despite persistent uncertainty around tariff policy and supply chain dynamics. The result reinforces the procedural volume recovery thesis for MedTech broadly: underlying surgical demand remains intact, and international expansion — cited by BSX management as a primary growth driver — continues to outperform domestic market trends. For MBS practitioners tracking device sector health and capital equipment availability, the BSX Q1 beat provides an early signal of sector resilience heading into mid-year.

Intuitive Surgical Q1 2026 da Vinci Procedure Volume Grows Near Guidance Ceiling — Robotic Bariatric Surgery Adoption Accelerates

Intuitive Surgical reported first-quarter 2026 da Vinci procedure growth near the upper range of analyst estimates (15–18% YoY), driven by continuing international market expansion and broadening application of robotic-assisted surgery in bariatric, thoracic, and urologic categories. ISRG shares closed at $483.62 on April 22, essentially flat from their April 11 level ($485.26), holding up considerably better than most MedTech peers during the period’s volatility. The primary near-term competitive variable — Johnson & Johnson’s OTTAVA surgical robotic system — received its De Novo submission in January 2026 and remains under active FDA review with no confirmed clearance timeline, though J&J leadership has indicated a 2026 decision is possible. For bariatric surgeons, robotic-assisted RYGB and sleeve gastrectomy continue to represent one of the fastest-growing ISRG application categories, with large academic and high-volume community programs driving adoption ahead of competitive alternatives entering the market.

Tirzepatide Dominates Semaglutide on Cost-Effectiveness — Saves $41,688 Per Patient With 0.506 Additional QALYs in First SURMOUNT-5-Based Model

This patient-level simulation — the first cost-effectiveness analysis to incorporate head-to-head data from the SURMOUNT-5 trial — found tirzepatide at maximum tolerated dose (MTD) to be economically dominant over semaglutide (MTD) from the U.S. societal perspective: the model generated per-patient cost savings of $41,688 alongside 0.506 additional QALYs and a positive incremental net health benefit (iNHB) of 0.784. Tirzepatide was dominant or highly cost-effective across all 9 scenario analyses at a $150,000/QALY willingness-to-pay threshold. At the population level (per 1,000 patients), the model predicts 70 fewer cases of type 2 diabetes, 10 fewer cardiovascular disease events, and 3.07 fewer years spent with moderate/severe OSA in the tirzepatide arm. The SURMOUNT-5 trial demonstrated tirzepatide achieved −20.2% vs. −13.7% weight loss at 72 weeks in a direct comparison. Funding: Eli Lilly; corresponding author is an Eli Lilly employee. Costello Medical (analytics) received Lilly payment.

GLP-1 Drug Users Face Unaddressed Nutritional Deficiency Risk — Only 12 Studies Examine Dietary Guidance With Semaglutide or Tirzepatide

A systematic scoping review published in Obesity Reviews by Dr. Marie Spreckley and colleagues at the MRC Epidemiology Unit, University of Cambridge, identified a near-total absence of standardized nutritional guidance protocols for patients prescribed GLP-1 receptor agonists for weight loss. Of the 12 studies identified that addressed nutrition alongside semaglutide or tirzepatide, none employed consistent protocols, and heterogeneity in nutritional assessment approaches precluded robust conclusions. Without structured dietary support, the appetite suppression produced by these agents creates compounding risk for protein inadequacy, micronutrient deficiency (vitamins D, B12, iron, calcium, and zinc), lean mass loss, hair loss, and osteoporosis — a clinical profile that metabolic and bariatric surgery programs have extensively characterized and managed in their post-surgical populations for decades. The review’s implication for MBS practitioners is significant: programs that have built longitudinal nutritional follow-up, dietitian oversight, and supplement protocols into their care model are structurally equipped to manage the nutritional risks now emerging in the rapidly expanding GLP-1-treated patient population.

Beyond GLP-1 Receptors: Emerging Drug Targets in the Obesity Market — GIPR, Glucagon, Amylin, and GDF15 Pathways Define the Next Wave

A Pharmaceutical Technology analyst commentary surveys the pipeline of anti-obesity pharmacotherapy extending beyond pure GLP-1 receptor agonism. With tirzepatide (Mounjaro/Zepbound) establishing the commercial case for dual GLP-1/GIP receptor co-agonism, the competitive frontier is advancing: Lilly’s retatrutide (LY3437943), a triple GLP-1/GIP/glucagon receptor agonist in Phase 3, targets additional thermogenic and energy expenditure pathways for potentially greater weight loss; Novo Nordisk’s CagriSema combines semaglutide with cagrilintide (amylin receptor agonist) and achieved 22.7% TBWL in REDEFINE 1; GDF15 receptor agonism (targeting appetite circuits independently of incretin biology) represents an early-stage pipeline with differentiated mechanism; and once-monthly GLP-1 formulations — including Pfizer’s PF-08653944 and oral semaglutide — reframe the market’s value proposition around adherence rather than efficacy alone. The obesity drug market, projected to reach over $130 billion annually by 2030, is approaching the mechanistic diversity of oncology. For the bariatric surgical community, the proliferation of effective pharmacotherapy raises the floor for nonsurgical weight loss while simultaneously generating the question that will define the field’s positioning: at what point does MBS’s unique combination of durability, metabolic depth, and one-time cost assertion require renewed articulation to patients, payors, and referring physicians?

Pfizer’s Once-Monthly GLP-1 Injectable Shows 10–12% Weight Loss at Week 28 — Monthly Dosing Could Commoditize the Novo/Lilly Duopoly

In a Motley Fool market analysis, James Brumley positions Pfizer’s investigational GLP-1 receptor agonist PF-08653944 — brought into the pipeline via Pfizer’s $10 billion Metsera acquisition — as a credible disruptor to the Novo Nordisk/Eli Lilly weight-loss drug duopoly. Phase 2b data through week 28 of a planned 64-week regimen showed weight loss of 10–12% at low and medium doses, comparable to weekly Wegovy and Zepbound. The critical differentiator: PF-08653944 requires only monthly rather than weekly subcutaneous injections — an adherence advantage in a market where 50–67% of GLP-1 users discontinue within one year, with cost and injection frequency as the primary drivers. Pfizer has planned more than 20 obesity trials for 2026, including 10 Phase 3 trials of PF-08653944 (one of which tests weekly dosing). Brumley argues the monthly formulation, even if modestly less efficacious, could intensify the already-underway price war between Novo and Lilly — Novo guided for a 5–13% revenue decline in 2026; Zepbound 2025 revenue of $13.5B (+175% YoY) was already showing price compression in Q4.

Eli Lilly declined modestly amid a confluence of headwinds: the FDA’s postmarketing safety signal requests for Foundayo (retained gastric contents, MACE, and DILI), emerging competition from Pfizer’s once-monthly injectable PF-08653944, and investor recalibration ahead of Q1 2026 earnings. Zepbound delivered $13.5B in 2025 revenue (+175% YoY), but Q4 growth showed price compression as the NVO/LLY price war intensified. Most analysts maintain Buy ratings with 12-month targets in the $1,100–$1,250 range. Near-term catalyst: Q1 2026 earnings release and Mounjaro/Zepbound volume data.

Novo Nordisk posted the period’s strongest gain (+5.1%) among tracked names, recovering from a sustained multi-quarter drawdown (−35%+ from 2024 highs). Commercial support came from oral Wegovy adoption (600,000+ U.S. patients since January 2026 launch) and CagriSema pipeline momentum (NDA filed December 2025; REDEFINE 1 confirmed 22.7% TBWL). However, Novo’s 2026 revenue guidance remains weak (−5% to −13%), and the late-2026 FDA decision on CagriSema is the defining near-term catalyst. NVO closed at $39.42 on April 22, representing partial recovery from prior lows.

Boston Scientific’s period chart tells two distinct stories: a decline of approximately 9% during the tariff-volatility window of April 12–21, followed by a sharp 8.99% single-session recovery on April 22 following a Q1 earnings beat. The V-shaped finish leaves BSX net −1.1% for the period — meaningfully better than peers MDT (−8.9%) and ABT (−14.7%). Full-year guidance was maintained; international market expansion and cardiovascular procedure volume were cited as primary growth drivers. The result reinforces procedural demand durability for the device sector as a whole.

Teleflex experienced the most significant decline among tracked names (−24.1%), falling from $178.90 to $135.79 over the period. This decline reflects ongoing valuation adjustment associated with the company’s strategic separation of its diversified device portfolio into higher-focus business units — a process characterized by investors as a de facto breakup. On April 22, TFX shares gapped up from a recent intraperiod low as buyers absorbed the restructuring discount. Teleflex’s vascular access and interventional device lines remain relevant to high-acuity MBS programs; the restructuring creates near-term uncertainty but may clarify business value over time.

Intuitive Surgical held up best among MedTech peers, closing essentially flat (−0.3% at $483.62) despite broad sector volatility. Q1 2026 da Vinci procedure data showed continued growth near the 15–18% YoY guidance range. Robotic bariatric surgery adoption — particularly robotic RYGB and sleeve gastrectomy at high-volume academic programs — represents one of the fastest-growing ISRG application categories. The OTTAVA De Novo remains in FDA review; J&J has indicated a 2026 clearance is possible but no date has been confirmed. ISRG’s relative stability signals investor confidence in the durability of the robotic surgery adoption cycle.